176 related articles for article (PubMed ID: 12139632)
1. Clonal analysis of cutaneous fibrous histiocytoma (dermatofibroma).
Hui P; Glusac EJ; Sinard JH; Perkins AS
J Cutan Pathol; 2002 Aug; 29(7):385-9. PubMed ID: 12139632
[TBL] [Abstract][Full Text] [Related]
2. Dermatofibroma is a clonal proliferative disease.
Chen TC; Kuo T; Chan HL
J Cutan Pathol; 2000 Jan; 27(1):36-9. PubMed ID: 10660130
[TBL] [Abstract][Full Text] [Related]
3. Dermatofibrosarcoma protuberans: an analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression.
Sasaki M; Ishida T; Horiuchi H; MacHinami R
Pathol Int; 1999 Sep; 49(9):799-806. PubMed ID: 10504551
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Li N; McNiff J; Hui P; Manfioletti G; Tallini G
Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
[TBL] [Abstract][Full Text] [Related]
5. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma.
Mori T; Misago N; Yamamoto O; Toda S; Narisawa Y
J Dermatol; 2008 Jul; 35(7):419-25. PubMed ID: 18705829
[TBL] [Abstract][Full Text] [Related]
6. The pathological distinction between "deep penetrating" dermatofibroma and dermatofibrosarcoma protuberans.
Wick MR; Ritter JH; Lind AC; Swanson PE
Semin Cutan Med Surg; 1999 Mar; 18(1):91-8. PubMed ID: 10188848
[TBL] [Abstract][Full Text] [Related]
7. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
[TBL] [Abstract][Full Text] [Related]
8. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
Kahn HJ; Fekete E; From L
Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
[TBL] [Abstract][Full Text] [Related]
9. Flow-cytometric DNA analysis in cutaneous fibrohistiocytic tumors.
Okita H; Ohtsuka T; Yamazaki S
Dermatology; 2003; 207(4):357-61. PubMed ID: 14657626
[TBL] [Abstract][Full Text] [Related]
10. p53 protein immunoreactivity in fibrohistiocytic tumors of the skin.
Lee CS; Chou ST
Pathology; 1998 Aug; 30(3):272-5. PubMed ID: 9770192
[TBL] [Abstract][Full Text] [Related]
11. [Differences of the molecular phenotypes and the histogenesis between dermatofibroma and dermatofibrosarcoma protuberans].
Xiong Y; Guo H; Zhang S; Zhang B; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):395-400. PubMed ID: 18677387
[TBL] [Abstract][Full Text] [Related]
12. Clonal composition of malignant fibrous histiocytoma: analysis by PCR-based assay of the human androgen receptor gene (HUMARA).
Fujita MQ; Hashida N; Shin M; Nakanishi H; Yoshihara W; Aozasa K
Oncology; 1998; 55(6):600-6. PubMed ID: 9778630
[TBL] [Abstract][Full Text] [Related]
13. Indeterminate fibrohistiocytic lesions of the skin: is there a spectrum between dermatofibroma and dermatofibrosarcoma protuberans?
Horenstein MG; Prieto VG; Nuckols JD; Burchette JL; Shea CR
Am J Surg Pathol; 2000 Jul; 24(7):996-1003. PubMed ID: 10895822
[TBL] [Abstract][Full Text] [Related]
14. CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Calikoglu E; Augsburger E; Chavaz P; Saurat JH; Kaya G
J Cutan Pathol; 2003 Mar; 30(3):185-9. PubMed ID: 12641778
[TBL] [Abstract][Full Text] [Related]
15. The expression levels and the differential expression of transforming growth factor-beta receptors in dermatofibroma and dermatofibrosarcoma protuberans.
Kubo M; Ihn H; Yamane K; Tamaki K
Br J Dermatol; 2006 May; 154(5):919-25. PubMed ID: 16634896
[TBL] [Abstract][Full Text] [Related]
16. COL1A1:PDGFB chimeric transcripts are not present in indeterminate fibrohistiocytic lesions of the skin.
Wang WL; Patel KU; Coleman NM; Smith-Zagone MJ; Ivan D; Reed JA; López-Terrada D; Lazar AJ; Prieto VG
Am J Dermatopathol; 2010 Apr; 32(2):149-53. PubMed ID: 19940748
[TBL] [Abstract][Full Text] [Related]
17. Tenascin expression in cutaneous fibrohistiocytic tumors. Immunohistochemical investigation of 24 cases.
Franchi A; Santucci M
Am J Dermatopathol; 1996 Oct; 18(5):454-9. PubMed ID: 8902090
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of platelet-derived growth factor and its receptors in fibrohistiocytic tumors.
Taniuchi K; Yamada Y; Nonomura A; Takehara K
J Cutan Pathol; 1997 Aug; 24(7):393-7. PubMed ID: 9274955
[TBL] [Abstract][Full Text] [Related]
19. Monoclonality of both pale cells and cuboidal cells of sclerosing hemangioma of the lung.
Niho S; Suzuki K; Yokose T; Kodama T; Nishiwaki Y; Esumi H
Am J Pathol; 1998 Apr; 152(4):1065-9. PubMed ID: 9546367
[TBL] [Abstract][Full Text] [Related]
20. nm23 protein expression and p53 immunoreactivity in cutaneous fibrohistiocytic tumors.
Lee CS; Clarke RA; Tran KT; Kearsley JH; Chou ST
Pathology; 1999 May; 31(2):123-6. PubMed ID: 10399167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
